替奈普酶治疗急性缺血性脑卒中  

Tenecteplase and Its Treatment for Acute Ischemic Stroke

作　　者：孙旭红[1] 吴菁[1] SUN Xu-hong;WU Jing(Department of Neurology,Shanghai Ninth People's Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200011,China)

机构地区：[1]上海交通大学医学院附属第九人民医院神经内科

出　　处：《中国临床神经科学》2019年第6期676-686,699,共12页Chinese Journal of Clinical Neurosciences

摘　　要：替奈普酶(TNK-tPA)是重组人组织型纤溶酶原激活物(rt-PA)经生物工程改造后的基因突变体,与rt-PA比较,TNK-tPA的纤维蛋白选择性更高、半衰期更长(可以静脉推注)、对于循环中的纤维蛋白原影响更小,对纤溶酶原激活物抑制剂的抵抗性更强。虽然TNK-tPA和rt-PA的作用机制相同.TNK-tPA溶栓更有优势。对于急性缺血性脑卒中的溶栓治疗.TNK-tPA和其与rt-PA的临床对照研究尚需要进一步证实TNK-tPA的安全性和有效性。文中从TNK-tPA的分子结构和临床用于急性缺血性脑卒中溶栓治疗的研究进行综述。Tenecteplase(TNK-tPA),a genetically engineered mutant tissue plasminogen activator(rt-PA),has a longer half-life,more selective in fibrin.It produces less systemic depletion of circulating fibrinogen,and has more resistant to plasminogen activator inhibitor compared to alteplase.It can be used single intravenously.Although TNK-tPA and rt・PA have the same mechanism of action,TNKtPA has properties that makes it a seemingly more advantageous thrombolytic.The literature on the pharmacodynamics and pharmacokinetics of TNK-tPA and its treatment of acute ischemic stroke were reviewed.

关 键 词：替奈普酶 急性缺血性脑卒中 重组人组织型纤溶酶原激活物 安全性 不同剂量 

分 类 号：R743[医药卫生—神经病学与精神病学]